Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial

Ottervanger, Jan Paul; Misier, Anand Ramdat; Zijlstra, Felix; Schalij, Martin J.; Wever, Eric F.D.; Jordaens, Luc; Henriques, José P.S.; Boer, Menko‐Jan de; Robbe, Hindrik W. J.; Wellens, Hein J.J.

doi:10.1016/j.ahj.2006.06.012

Cited by 8 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Our finding that early VT is not associated with failed PCI or an adverse prognosis does not change the rationale of this study. Early ventricular tachycardia is not an inclusion criteria of the DAPA study and randomisation takes place 30 days after STEMI, a time period after which the occurrence of ventricular arrhythmias is generally considered more malignant.…”

Section: Multivariate Analysismentioning

confidence: 73%

Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention

Timmer

Breet

Svilaas³

et al. 2010

NHJL

View full text Add to dashboard Cite

Background. We investigated the association between clinical characteristics, angiographic data and ventricular arrhythmia in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Methods. In patients with STEMI (n=225), a Holter analysis was performed the first 12 hours after primary PCI.Results. A total of 151 (66%) patients had ≥1 episode of ventricular tachycardia (VT). Age <70 years (RR 4.9, 95% CI 1.8 to 12.7), TIMI 0-1 pre-PCI (RR 2.6, 95% CI 1.1 to 6.1) and peak CK (RR 3.5, 95% CI 1.9 to 5.8) were independent predictors of VT. One-year mortality was 7%, no association between mortality and presence of early VT was found. Conclusion. Ventricular tachycardia is common

show abstract

Section: Multivariate Analysismentioning

confidence: 73%

Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention

Timmer

Breet

Svilaas³

et al. 2010

NHJL

View full text Add to dashboard Cite

show abstract

“…Microvolt TWA is not visually detectable on continuous ECG but can be measured during bicycle or treadmill exercise with spectral analysis [ 24 ]. First experiences in the canine model [ 25 ] demonstrated that increasing TWA was associated with lower ventricular fibrillation threshold.…”

Section: Risk Stratification Of Scd In Patients After Myocardial Infarction Without Severe Left Ventricular Dysfunctionmentioning

confidence: 99%

Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification

Pannone

Falasconi

Cianfanelli

et al. 2021

JCM

View full text Add to dashboard Cite

Sudden cardiac death (SCD) is the leading cause of cardiovascular mortality in patients with coronary artery disease without severe systolic dysfunction and in heart failure with preserved ejection fraction. From a global health perspective, while risk may be lower, the absolute number of SCDs in patients with left ventricle ejection fraction >35% is higher than in those with severely reduced left ventricle ejection fraction (defined as ≤35%). Despite these observations and the high amount of available data, to date there are no clear recommendations to reduce the sudden cardiac death burden in the population with mid-range or preserved left ventricle ejection fraction. Ongoing improvements in risk stratification based on electrophysiological and imaging techniques point towards a more precise identification of patients who would benefit from ICD implantation, which is still an unmet need in this subset of patients. The aim of this review is to provide a state-of-the-art approach in sudden cardiac death risk stratification of patients with mid-range and preserved left ventricular ejection fraction and one of the following etiologies: ischemic cardiomyopathy, heart failure, atrial fibrillation or myocarditis.

show abstract

The future of implantable defibrillator and cardiac resynchronization therapy trials

Saksena

Nagarakanti

2008

J Interv Card Electrophysiol

View full text Add to dashboard Cite

Implantable cardioverter defibrillator (ICD) trials were initially limited to survivors of sudden death. The focus of defibrillator trials in the last decade has been in prophylactic implantation of the device in high risk populations for the prevention of sudden cardiac death. It is the contention in this review that the new focus for implantable defibrillator trials in 2008 and beyond will be on more selective and focused use of this therapy. This could be achieved by selecting ICD patients based on their pathophysiologic and genetic risk. Increasing effort will also be placed on using the device for prevention of spontaneous malignant ventricular tachyarrhythmias and the index clinical sudden death event. Finally, implantable defibrillators will be used in combination in a "hybrid" therapy approach. ICDs will be increasingly combined either with ventricular tachycardia ablation or ventricular fibrillation ablation using catheter techniques. With the addition of cardiac resynchronization therapy in these devices, new clinical trials that use cardiac resynchronization therapy as an early intervention in specific high risk heart failure populations and refinement of the CRT technique to improved optimal results are in progress. Finally, combining ICD devices and regenerative medicine approaches to myocardial replacement therapy are being explored.

show abstract

Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial

Cited by 8 publications

References 37 publications

Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention

Predictors of ventricular tachyarrhythmia in high-risk myocardial infarction patients treated with primary coronary intervention

Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification

The future of implantable defibrillator and cardiac resynchronization therapy trials

Contact Info

Product

Resources

About